Doniesienia konferencyjne

Jakubowski S, Kawalec P

Analysis of Anatomical Therapeutic Chemical (ATC) Classification and Therapeutic Area of Orphan Medicinal Products (OMP) vs Reimbursement for These Drugs in 11 European Countries

Conference/Value in Health Info 2024-11, ISPOR Europe 2024, Barcelona, Spain Value in Health, Volume 27, Issue 12, S2 (December 2024)

Wex J, Holko P, Kawalec P, Le Rouzo G

Lifetime Cost of Orphan Therapies in Paediatric Indications in Europe

Conference/Value in Health Info 2023-11, ISPOR Europe 2023, Copenhagen, Denmark Value in Health, Volume 26, Issue 11, S2 (December 2023)

Jakubowski S, Kawalec P, Holko P

CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

Conference/Value in Health Info 2022-11, ISPOR Europe 2022, Vienna, Austria Value in Health, Volume 25, Issue 12S (December 2022)

Shupo F, Abrams K, Ademi Z, Wayi-Wayi G, Zibelnik N, Kirchmann M, Rutherford C, Holko P, Kawalec P, Makarounas-Kirchmann K

Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia

Conference/Value in Health Info 2022-11, ISPOR Europe 2022, Vienna, Austria Value in Health, Volume 25, Issue 12S (December 2022)

Jakubowski S, Kawalec P, Malinowski K

Relationship/Association between Clinical Potential of Orphan Drugs and Registration Status Assigned By the European Medicines Agency: Selected Aspects

Conference/Value in Health Info 2022-05, ISPOR 2022, Washington, DC, USA Value in Health, Volume 25, Issue 6, S1 (June 2022)